My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.760 -0.060 (-3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tiziana Life Sciences Ltd - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
7 Over-Hyped Stocks to Sell Before They Plunge
It wasn't too long ago that these stocks were considered hot commodities. But now they're just overhyped stocks to sell. 
Via InvestorPlace
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says
Tesla shares fell only slightly. And auto recalls are nothing new. Recall how, in 1981, Ford issued a recall on 21 million vehicles. 
Via Benzinga
Topics Product Recall
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024
After a volatile 2023, equity markets appear to be rallying into 2024. Can they keep it up? 
Via Benzinga
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab
--News Direct-- 
Via News Direct
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab
This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS)... 
Via Benzinga
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
SPDR ETF Report For Tuesday, November 21
Via Talk Markets
Topics ETFs
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders need to know about this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic worth checking out on Wednesday and we have all the latest news happening this morning! 
Via InvestorPlace
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
--News Direct-- 
Via News Direct
Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
Tiziana Life Sciences reports six-month PET scan results for MS patients
--News Direct-- 
Via News Direct
Tiziana Life Sciences reports six-month PET scan results for MS patients
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company... 
Via TheNewswire.com
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana to Announce Six-Month Human Safety and Biomarker Data at the ECTRIMS Annual Congress, Following-Up from Positive Outcomes Data Presented in June
--News Direct-- 
Via News Direct
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June
Tiziana (NASDAQ: TLSA) is following up with anticipated human data and announced the acceptance of a late-breaking poster at the 39th Congress of the Europea 
Via Benzinga
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tiziana Advances Phase 2 Site Selection for Its Lead Clinical Program in Non-Active Secondary Progressive Multiple Sclerosis (SPMS) and The Company Prepares for Six-Month Clinical Data Update
--News Direct-- 
Via News Direct
Cathie Wood Sells $25 Million In Tesla Stock As TSLA Flashes Aggressive Buy Signal
Wood's Ark Invest unloaded nearly 100,000 TSLA shares Wednesday. 
Via Investor's Business Daily
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.